New stock news | Hanson ETI submits documents to the Hong Kong Stock Exchange

According to the financial and economic news app, it was disclosed by the Hong Kong Stock Exchange on December 3 that Hanseatic Biotechnology (Wuhan) Co., Ltd. (referred to as Hanseatic) submitted an application to the Hong Kong Stock Exchange Main Board, with Guotai Junan International as its exclusive sponsor. The prospectus reveals that Hanseatic is a biotechnology company with independent expertise and experience in structural biology, translational medicine, and clinical development. Since 2016, the company has developed a product pipeline, including one core product and nine other candidate products. It is reported that the core product HX009 is a self-developed fusion protein of anti-PD-1 (an immune checkpoint receptor) / SIRP dual-function antibody. During the reporting period and until the latest feasible date, the company has completed Phase I clinical trials of HX009 in Australia and China.